Published on

Medicine – Acute Lymphoblastic Leukaemia (ALL)

Acute lymphoblastic leukaemia (ALL), also called acute lymphocytic leukaemia, is an aggressive haematological malignancy characterised by the uncontrolled proliferation of immature lymphoid precursor cells (lymphoblasts) in the bone marrow, peripheral blood and sometimes extramedullary tissues.

ALL is the most common childhood cancer, although it can also occur in adults.

The accumulation of lymphoblasts suppresses normal haematopoiesis, causing anaemia, neutropenia and thrombocytopenia.

Important Clinical Principle

ALL commonly presents in children with fever, pallor, bruising, infections, bone pain and hepatosplenomegaly. The diagnosis is established using bone marrow examination, immunophenotyping and genetic studies.

1. Epidemiology

  • ALL predominantly affects children.
  • Peak incidence occurs between 2 and 5 years of age.
  • It is the most common acute leukaemia in children.
  • Most childhood cases arise from B-cell precursors.
  • T-cell ALL is less common and may present with a mediastinal mass.
  • ALL also affects adults, particularly older adults, in whom outcomes are generally less favourable.
Prognosis: Older teaching materials quote a cure rate of approximately 70% with chemotherapy. With modern risk-adapted treatment, long-term survival in children is now commonly above 85–90% in well-resourced treatment settings. Adult outcomes are more variable.

2. Pathophysiology

ALL arises from genetic abnormalities affecting immature B-cell or T-cell precursors.

These abnormalities cause uncontrolled lymphoblast proliferation and impaired differentiation.

Pathophysiology Flowchart

Genetic Abnormalities Immature lymphoid precursors Uncontrolled Lymphoblast Proliferation Bone Marrow Infiltration Suppression of normal blood cells Marrow Failure and Infiltration Anaemia / Infection / Bleeding Possible CNS or Testicular Disease Lymphoid organ infiltration

3. Classification

ALL is broadly classified into two major immunophenotypic groups.

Type Characteristics
B-ALL Most common type in children; arises from immature B-cell precursors.
T-ALL Arises from immature T-cell precursors; may cause mediastinal enlargement.

Modern classification also incorporates genetic abnormalities, which influence prognosis and treatment.

4. Clinical Features

ALL commonly presents with bone marrow failure and infiltration of lymphoid or extramedullary tissues.

A. Fever

Fever is a common presenting feature and may occur due to infection or the underlying malignancy itself.

Infection must always be considered, particularly when neutropenia is present.

B. Anaemia

Anaemia results from suppression of normal red blood cell production.

Clinical features include:

  • Pallor.
  • Fatigue and lethargy.
  • Dyspnoea.
  • Dizziness.
  • Reduced exercise tolerance.

C. Bleeding

Thrombocytopenia causes an increased bleeding tendency.

Manifestations include:

  • Petechiae.
  • Purpura.
  • Epistaxis.
  • Gum bleeding.
  • Easy bruising.

D. Infection

Neutropenia and impaired immune function increase susceptibility to infections.

Medical Emergency: Febrile neutropenia requires urgent assessment and prompt empiric antimicrobial treatment.

E. Hepatosplenomegaly and Lymphadenopathy

Leukaemic infiltration may cause:

  • Hepatomegaly.
  • Splenomegaly.
  • Generalised lymphadenopathy.

F. Bone and Joint Pain

Bone pain is an important presenting feature, particularly in children.

It results from expansion and infiltration of the bone marrow.

Children may present with limping, refusal to walk or symptoms resembling musculoskeletal disease.

G. Central Nervous System (CNS) Involvement

ALL can infiltrate the meninges and central nervous system.

Possible manifestations include:

  • Headache.
  • Vomiting.
  • Cranial nerve palsies.
  • Diplopia.
  • Seizures.
  • Altered consciousness.

CNS involvement may occur even when neurological symptoms are absent, making CNS-directed treatment an essential component of ALL therapy.

H. Testicular Involvement

Testicular infiltration may occur, particularly in boys, and can present as painless testicular enlargement.

I. Mediastinal Mass

T-ALL may produce a large anterior mediastinal mass.

This may cause:

  • Cough.
  • Dyspnoea.
  • Stridor.
  • Superior vena cava obstruction.

5. Peripheral Blood Film

The peripheral blood film may demonstrate circulating lymphoblasts.

Lymphoblasts generally demonstrate:

  • High nuclear-to-cytoplasmic ratio.
  • Fine chromatin.
  • Variable nucleoli.
  • Relatively scant cytoplasm.

Unlike AML, Auer rods are absent in ALL.

Lymphoblast Schematic

Large nucleus Nucleolus Scant cytoplasm Lymphoblast

Simplified educational illustration; not an actual blood film.

Examination Pearl: Auer rods are absent in ALL. Their presence in a blast strongly supports myeloid differentiation.

6. Investigations and Diagnosis

A. Full Blood Count

Possible findings include:

  • Anaemia.
  • Thrombocytopenia.
  • Neutropenia.
  • Elevated, normal or reduced total white cell count.
  • Circulating lymphoblasts.

B. Peripheral Blood Film

May reveal lymphoblasts, although circulating blasts are not present in every patient.

C. Bone Marrow Examination

Bone marrow aspiration and biopsy are central to diagnosis.

ALL is generally associated with at least 20% lymphoblasts in the bone marrow, although diagnostic criteria and distinctions from lymphoblastic lymphoma depend on classification and clinical context.

D. Immunophenotyping

Flow cytometry distinguishes B-ALL from T-ALL and helps exclude AML.

Marker Association
TdTImmature lymphoid precursors
CD19B-cell lineage
CD10Commonly expressed in B-ALL
CD22 / cytoplasmic CD79aB-cell lineage
Cytoplasmic or surface CD3T-cell lineage
CD7Common T-cell marker
MPOUsually negative in ALL

E. Cytogenetic and Molecular Testing

Genetic abnormalities influence prognosis and guide treatment.

Abnormality Significance
ETV6::RUNX1, t(12;21)Often favourable prognosis in childhood B-ALL
High hyperdiploidyGenerally favourable in childhood B-ALL
BCR::ABL1, t(9;22)Philadelphia chromosome-positive ALL; requires targeted treatment
KMT2A rearrangementImportant high-risk association, particularly in infants
HypodiploidyGenerally adverse-risk disease
BCR::ABL1-like ALLMolecularly defined subgroup with variable actionable alterations

F. Biochemical Investigations

  • LDH may be elevated due to rapid cellular turnover.
  • Uric acid may be elevated.
  • Electrolyte abnormalities may occur.
  • Renal function should be assessed.
  • Liver function is evaluated before treatment.

G. Coagulation Profile

Coagulation abnormalities may occur.

DIC is not a defining or consistently present feature of ALL. It is particularly associated with acute promyelocytic leukaemia, a subtype of AML.

The historical figure of DIC in approximately 10% of ALL cases should not be treated as a universal diagnostic characteristic.

H. Lumbar Puncture

Cerebrospinal fluid examination is used to assess CNS involvement when clinically appropriate and safe, as part of specialist diagnostic and treatment protocols.

Diagnostic Flowchart

Suspected ALL Fever / pallor / bruising / bone pain Blood Count and Blood Film Cytopenias ± circulating lymphoblasts Bone Marrow Examination Morphology / lymphoblast assessment Immunophenotyping B-ALL / T-ALL and genetic studies Risk-Based Treatment Planning Genetics / age / CNS status / MRD Specialist multi-phase treatment

7. Treatment

ALL requires prolonged, multi-phase systemic therapy with CNS-directed treatment.

A. Induction Therapy

The aim is to achieve remission by eliminating most leukaemic cells.

Common drug classes include:

  • Corticosteroids.
  • Vincristine.
  • Asparaginase.
  • Anthracyclines in selected regimens.

B. Consolidation / Intensification

Further chemotherapy aims to eliminate residual leukaemic cells and reduce relapse risk.

C. CNS-Directed Therapy

CNS prophylaxis is essential because the CNS can act as a sanctuary site for leukaemic cells.

Treatment commonly includes intrathecal chemotherapy, such as methotrexate, with systemic CNS-active therapy.

Cranial radiotherapy is now reserved for selected circumstances rather than used routinely in most modern paediatric protocols.

D. Maintenance Therapy

Maintenance therapy is usually prolonged and commonly includes oral mercaptopurine and methotrexate-based treatment.

E. Targeted Therapy

Philadelphia chromosome-positive ALL requires a BCR::ABL1 tyrosine kinase inhibitor, combined with an appropriate systemic treatment regimen.

F. Immunotherapy

Selected patients may receive:

  • Blinatumomab: A CD19-directed bispecific T-cell engager.
  • Inotuzumab ozogamicin: A CD22-directed antibody–drug conjugate.
  • CD19-directed CAR T-cell therapy: For eligible relapsed or refractory B-ALL.

G. Stem Cell Transplantation

Allogeneic haematopoietic stem cell transplantation may be considered for selected high-risk, persistent or relapsed disease.

H. Supportive Care

  • Blood product transfusions.
  • Infection prevention and treatment.
  • Tumour lysis syndrome prevention.
  • Nutritional and psychosocial support.
  • Monitoring for treatment-related complications.

Treatment Flowchart

Confirmed ALL Risk-adapted treatment protocol Induction Therapy Achieve remission Consolidation / Intensification Reduce residual leukaemic cells Maintenance Therapy Prolonged relapse prevention Ongoing Monitoring MRD / relapse surveillance CNS-directed therapy is integrated throughout treatment.

Simplified treatment sequence. Actual protocols include overlapping phases and additional therapy according to risk and response.

8. Prognosis

ALL prognosis depends on:

  • Age.
  • Immunophenotype.
  • Genetic abnormalities.
  • Treatment response.
  • Measurable residual disease (MRD).

Children generally have better outcomes than adults.

With contemporary risk-adapted treatment, long-term survival exceeds 85–90% in many paediatric treatment programmes, although results vary by subtype and healthcare setting.

Adult ALL outcomes are more variable, and high-risk genetic abnormalities or persistent MRD may predict a greater risk of relapse.

9. ALL vs AML

Feature ALL AML
Cell lineageLymphoid precursorsMyeloid precursors
Typical populationPredominantly childrenPredominantly adults
Blood filmLymphoblastsMyeloblasts
Auer rodsAbsentMay be present
TdTCommonly positiveUsually negative
MPOUsually negativeOften positive
CNS involvementImportant sanctuary siteLess common at presentation
Mediastinal massParticularly T-ALLLess characteristic
Gingival infiltrationLess characteristicParticularly monocytic AML
TreatmentMulti-phase chemotherapy, CNS prophylaxis, targeted/immunotherapyChemotherapy, targeted therapy ± transplantation

10. High-Yield Examination Summary

Feature Key Point
DefinitionMalignant proliferation of lymphoblasts
Typical populationChildren
Peak age2–5 years
Main presentationBone marrow failure
Clinical featuresFever, pallor, bleeding, infection
Other findingsBone pain, lymphadenopathy, hepatosplenomegaly
CNS involvementImportant clinical and treatment consideration
Blood filmCirculating lymphoblasts may be present
Auer rodsAbsent
ImmunophenotypeTdT+, with B- or T-lineage markers
DiagnosisBone marrow, flow cytometry and genetic testing
LDHOften elevated
DICNot a characteristic defining feature
TreatmentMulti-phase chemotherapy and CNS-directed therapy
Targeted therapyTKIs for BCR::ABL1-positive ALL
PrognosisOften excellent in children; more variable in adults

11. Key Examination Pearls

  • ALL is the most common childhood cancer.
  • The peak incidence occurs between 2 and 5 years of age.
  • Bone marrow failure causes anaemia, infection and bleeding.
  • Bone and joint pain may be prominent in children.
  • Hepatosplenomegaly and lymphadenopathy may occur.
  • T-ALL may present with an anterior mediastinal mass.
  • CNS involvement is clinically important, even when asymptomatic.
  • Auer rods are absent in ALL.
  • TdT is a characteristic marker of lymphoblast immaturity.
  • Bone marrow examination, immunophenotyping and molecular studies establish the diagnosis.
  • CNS prophylaxis is an essential component of treatment.
  • MRD is a major prognostic and treatment-guiding marker.
  • Modern paediatric ALL outcomes are substantially better than historical cure-rate estimates.
Most Important Examination Point

A child presenting with fever, pallor, bruising, bone pain and hepatosplenomegaly, together with circulating lymphoblasts, should raise suspicion of acute lymphoblastic leukaemia.

Clinical Note

Suspected ALL requires prompt specialist assessment. Fever with neutropenia, significant bleeding, respiratory compromise from a mediastinal mass or neurological deterioration requires emergency management.

Kembara Xtra – Medicine Revision Notes

Image description
0 Comments